SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

INTRODUCTION: The use of immune-checkpoint inhibitors has drastically improved the management of patients with non-small cell lung cancer (NSCLC), but innate and acquired resistances are hurdles needed to be solved. Immunomodulatory drugs that can reinvigorate the immune cytotoxic activity, in combi...

Full description

Saved in:
Bibliographic Details
Published in:J Immunother Cancer
Main Authors: Redin, Esther, Garmendia, Irati, Lozano, Teresa, Serrano, Diego, Senent, Yaiza, Redrado, Miriam, Villalba, Maria, De Andrea, Carlos E, Exposito, Francisco, Ajona, Daniel, Ortiz-Espinosa, Sergio, Remirez, Ana, Bertolo, Cristina, Sainz, Cristina, Garcia-Pedrero, Juana, Pio, Ruben, Lasarte, Juan, Agorreta, Jackeline, Montuenga, Luis M, Calvo, Alfonso
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group 2021
Subjects:
Clinical/Translational Cancer Immunotherapy
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7931761/
https://ncbi.nlm.nih.gov/pubmed/33658304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001496
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items